{"id":8969,"date":"2023-11-03T06:28:12","date_gmt":"2023-11-03T06:28:12","guid":{"rendered":"https:\/\/infundpros.com\/business\/blockbuster-weight-loss-drugs-boost-pharmaceutical-companies-novo-nordisk-and-eli-lilly\/"},"modified":"2023-11-03T06:28:13","modified_gmt":"2023-11-03T06:28:13","slug":"blockbuster-weight-loss-drugs-boost-pharmaceutical-companies-novo-nordisk-and-eli-lilly","status":"publish","type":"post","link":"https:\/\/infundpros.com\/?p=8969","title":{"rendered":"Blockbuster weight-loss drugs boost pharmaceutical companies Novo Nordisk and Eli Lilly"},"content":{"rendered":"
\n

\n As prescriptions for weight-loss and diabetes drugs skyrocket, so too has revenue for drugmakers Novo Nordisk and Eli Lilly.\n <\/p>\n

\n On Thursday, Novo Nordisk, the Denmark-based company behind Ozempic and Wegovy, reported a 29% increase in sales to $8.4 billion for the third quarter. Eli Lilly, which makes diabetes drug Mounjaro, reported a 37% revenue increase to $9.5 billion in the third quarter.\n <\/p>\n

\n The pharmaceutical companies are two of the biggest beneficiaries of the recent weight-loss drug frenzy, with Novo Nordisk catapulting to Europe\u2019s most valuable company in September.\n <\/p>\n

\n Both Ozempic and Mounjaro are injectable prescription medicines intended for adults with diabetes, though both are often prescribed off-label for weight loss. Wegovy was approved in 2021 for obesity treatment.\n <\/p>\n

\n The medicines are so popular in the United States that demand has outpaced both Eli Lilly and Novo Nordisk\u2019s ability to produce the drugs.\n <\/p>\n

\n The medicines work by reducing patients\u2019 appetites \u2013 and they are particularly popular in the United States. Approximately 1.7% of America\u2019s population has been prescribed a semaglutide in 2023, up 40-fold in the past five years. Semaglutides are a class of medication that aids insulin production; the class includes Ozempic and Wegovy. Novo Nordisk reported that its obesity care sales grew 174% in the first nine months of 2023, mainly driven by US demand.\n <\/p>\n

\n The success of Novo Nordisk and Eli Lilly\u2019s drugs has inspired other companies to dive into the prescription weight-loss business, including WeightWatchers, now known as WW International. In March, the diet company announced it would buy Sequence, a telehealth subscription service that connects patients with doctors who can prescribe weight-loss and diabetes drugs, including Ozempic and Mounjaro.\n <\/p>\n

\n However, while the injected medicines have proven extremely effective for weight loss, one study suggests that people taking the drugs may be at higher risk for serious digestive problems.\n <\/p>\n<\/p><\/div>\n

Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

As prescriptions for weight-loss and diabetes drugs skyrocket, so too has revenue for drugmakers Novo Nordisk and Eli Lilly. On Thursday, Novo…<\/p>\n","protected":false},"author":1,"featured_media":8970,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":{"0":"post-8969","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business"},"yoast_head":"\nBlockbuster weight-loss drugs boost pharmaceutical companies Novo Nordisk and Eli Lilly | inFundPros<\/title>\n<meta name=\"description\" content=\"As prescriptions for weight-loss and diabetes drugs skyrocket, so too has revenue for drugmakers Novo Nordisk and Eli Lilly. On Thursday, Novo Nordisk,\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/infundpros.com\/?p=8969\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Blockbuster weight-loss drugs boost pharmaceutical companies Novo Nordisk and Eli Lilly | inFundPros\" \/>\n<meta property=\"og:description\" content=\"As prescriptions for weight-loss and diabetes drugs skyrocket, so too has revenue for drugmakers Novo Nordisk and Eli Lilly. On Thursday, Novo Nordisk,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/infundpros.com\/?p=8969\" \/>\n<meta property=\"og:site_name\" content=\"inFundPros\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-03T06:28:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-03T06:28:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/11\/gettyimages-1771217813.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"450\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Press Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Press Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/infundpros.com\/?p=8969#article\",\"isPartOf\":{\"@id\":\"https:\/\/infundpros.com\/?p=8969\"},\"author\":{\"name\":\"Press Room\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff\"},\"headline\":\"Blockbuster weight-loss drugs boost pharmaceutical companies Novo Nordisk and Eli Lilly\",\"datePublished\":\"2023-11-03T06:28:12+00:00\",\"dateModified\":\"2023-11-03T06:28:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/infundpros.com\/?p=8969\"},\"wordCount\":312,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/infundpros.com\/#organization\"},\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/infundpros.com\/?p=8969#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/infundpros.com\/?p=8969\",\"url\":\"https:\/\/infundpros.com\/?p=8969\",\"name\":\"Blockbuster weight-loss drugs boost pharmaceutical companies Novo Nordisk and Eli Lilly | inFundPros\",\"isPartOf\":{\"@id\":\"https:\/\/infundpros.com\/#website\"},\"datePublished\":\"2023-11-03T06:28:12+00:00\",\"dateModified\":\"2023-11-03T06:28:13+00:00\",\"description\":\"As prescriptions for weight-loss and diabetes drugs skyrocket, so too has revenue for drugmakers Novo Nordisk and Eli Lilly. On Thursday, Novo Nordisk,\",\"breadcrumb\":{\"@id\":\"https:\/\/infundpros.com\/?p=8969#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/infundpros.com\/?p=8969\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/infundpros.com\/?p=8969#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/infundpros.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Blockbuster weight-loss drugs boost pharmaceutical companies Novo Nordisk and Eli Lilly\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/infundpros.com\/#website\",\"url\":\"https:\/\/infundpros.com\/\",\"name\":\"Fintech Advance\",\"description\":\"Latest Finance and Tech News and Updates\",\"publisher\":{\"@id\":\"https:\/\/infundpros.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/infundpros.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/infundpros.com\/#organization\",\"name\":\"Fintech Advance\",\"url\":\"https:\/\/infundpros.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png\",\"contentUrl\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png\",\"width\":409,\"height\":70,\"caption\":\"Fintech Advance\"},\"image\":{\"@id\":\"https:\/\/infundpros.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff\",\"name\":\"Press Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/infundpros.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png\",\"contentUrl\":\"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png\",\"caption\":\"Press Room\"},\"sameAs\":[\"https:\/\/infundpros.com\"],\"url\":\"https:\/\/infundpros.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Blockbuster weight-loss drugs boost pharmaceutical companies Novo Nordisk and Eli Lilly | inFundPros","description":"As prescriptions for weight-loss and diabetes drugs skyrocket, so too has revenue for drugmakers Novo Nordisk and Eli Lilly. On Thursday, Novo Nordisk,","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/infundpros.com\/?p=8969","og_locale":"en_US","og_type":"article","og_title":"Blockbuster weight-loss drugs boost pharmaceutical companies Novo Nordisk and Eli Lilly | inFundPros","og_description":"As prescriptions for weight-loss and diabetes drugs skyrocket, so too has revenue for drugmakers Novo Nordisk and Eli Lilly. On Thursday, Novo Nordisk,","og_url":"https:\/\/infundpros.com\/?p=8969","og_site_name":"inFundPros","article_published_time":"2023-11-03T06:28:12+00:00","article_modified_time":"2023-11-03T06:28:13+00:00","og_image":[{"width":800,"height":450,"url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/11\/gettyimages-1771217813.jpg","type":"image\/jpeg"}],"author":"Press Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Press Room","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/infundpros.com\/?p=8969#article","isPartOf":{"@id":"https:\/\/infundpros.com\/?p=8969"},"author":{"name":"Press Room","@id":"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff"},"headline":"Blockbuster weight-loss drugs boost pharmaceutical companies Novo Nordisk and Eli Lilly","datePublished":"2023-11-03T06:28:12+00:00","dateModified":"2023-11-03T06:28:13+00:00","mainEntityOfPage":{"@id":"https:\/\/infundpros.com\/?p=8969"},"wordCount":312,"commentCount":0,"publisher":{"@id":"https:\/\/infundpros.com\/#organization"},"articleSection":["Business"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/infundpros.com\/?p=8969#respond"]}]},{"@type":"WebPage","@id":"https:\/\/infundpros.com\/?p=8969","url":"https:\/\/infundpros.com\/?p=8969","name":"Blockbuster weight-loss drugs boost pharmaceutical companies Novo Nordisk and Eli Lilly | inFundPros","isPartOf":{"@id":"https:\/\/infundpros.com\/#website"},"datePublished":"2023-11-03T06:28:12+00:00","dateModified":"2023-11-03T06:28:13+00:00","description":"As prescriptions for weight-loss and diabetes drugs skyrocket, so too has revenue for drugmakers Novo Nordisk and Eli Lilly. On Thursday, Novo Nordisk,","breadcrumb":{"@id":"https:\/\/infundpros.com\/?p=8969#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/infundpros.com\/?p=8969"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/infundpros.com\/?p=8969#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/infundpros.com\/"},{"@type":"ListItem","position":2,"name":"Blockbuster weight-loss drugs boost pharmaceutical companies Novo Nordisk and Eli Lilly"}]},{"@type":"WebSite","@id":"https:\/\/infundpros.com\/#website","url":"https:\/\/infundpros.com\/","name":"Fintech Advance","description":"Latest Finance and Tech News and Updates","publisher":{"@id":"https:\/\/infundpros.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/infundpros.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/infundpros.com\/#organization","name":"Fintech Advance","url":"https:\/\/infundpros.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/infundpros.com\/#\/schema\/logo\/image\/","url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png","contentUrl":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/tech-logo.png","width":409,"height":70,"caption":"Fintech Advance"},"image":{"@id":"https:\/\/infundpros.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/infundpros.com\/#\/schema\/person\/87f7e632b195ea95c91503d9281f5eff","name":"Press Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/infundpros.com\/#\/schema\/person\/image\/","url":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png","contentUrl":"https:\/\/infundpros.com\/wp-content\/uploads\/2023\/10\/avatar_user_1_1697230663-96x96.png","caption":"Press Room"},"sameAs":["https:\/\/infundpros.com"],"url":"https:\/\/infundpros.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts\/8969","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8969"}],"version-history":[{"count":1,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts\/8969\/revisions"}],"predecessor-version":[{"id":8971,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/posts\/8969\/revisions\/8971"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=\/wp\/v2\/media\/8970"}],"wp:attachment":[{"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8969"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8969"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/infundpros.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8969"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}